CPT codes 81270 (JAK2), 81338 (MPL), 81339 (MPL), 81279 (JAK2 exons 12 and 13), 81219 (CALR), and 0027U (JAK2 exons 12-15) are considered medically necessary for the following ICD-10-CM codes when criteria in Indications and Limitations of Coverage are met: Group 14 Codes
CPT® (CDT codes and descriptions are copyright American Dental Association) | |
---|---|
86900 | |
ICD-10-CM | |
C58 | Malignant neoplasm of placenta |
D61.81 | Pancytopenia |
CPT Code Information 81270- JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant
Other mutations that may occur in the JAK2 gene will not be detected. In vitro studies have indicated that this assay has an analytical sensitivity of 1%. This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
The JAK2 V617F mutation is associated with myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis. This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA.
Mutations occurring outside of the analyzed region of the JAK2 gene will not be detected by this assay. This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. Reverse transcription polymerase chain reaction RT-PCR and Sanger sequencing
The JAK2 mutation test may be used, along with other tests such as CALR mutation and MPL mutation testing, to help diagnose bone marrow disorders that lead to the production of too many blood cells. These disorders are known as myeloproliferative neoplasms (MPNs).
JAK2 Mutation Analysis. JAK2 Mutation Analysis provides targeted detection of mutations in the JAK2 gene using DNA extracted from blood or bone marrow specimens. This test is used for diagnostic, prognostic, and predictive purposes associated with Hematological disorders.
Somatic mutations in the JAK2 gene are associated with essential thrombocythemia, a disorder characterized by an increased number of platelets, the blood cells involved in normal blood clotting.
CPT Codes*: JAK2 V617F Only: 81270 JAK2 V617F and EXON 12-14 run concurrently or by reflex: 81270, 81403.
1.
Your doctor can use a blood sample or a bone marrow sample from a biopsy to check your JAK2 gene. You can get results in four to six days, but your lab may take longer. SOURCES: Mayo Clinic: “Polycythemia Vera,” “Complete blood count (CBC),” “Bone marrow biopsy and aspiration.”
[4] According to the World Health Organization, essential thrombocytosis is a disease that occurs when the platelet count is more than 450000 with the presence of Janus kinase 2 (JAK2), Calreticulin (CALR) or myeloproliferative leukemia virus oncogene (MPL) mutation, lacking clonal or reactive causes.
The condition is thought to be caused in part by a mutation in a gene called JAK2. Normally, JAK2 regulates the production of different types of blood cells, keeping them in balance. More than 95 percent of people with polycythemia vera have a mutation in JAK2 that leads to the production of too many red blood cells.
The JAK2 Wild Type Reference Standard is a highly-characterized, biologically-relevant quality control material used to assess the performance of assays that detect somatic mutations, such as Sanger and qPCR sequencing assays.
JAK2 exon 12 mutations define a distinctive myeloproliferative syndrome that affects patients who currently receive a diagnosis of polycythemia vera or idiopathic erythrocytosis.
I answer: If you follow the WHO-based algorithm and do a JAK2 test and EPO level to work up a suspected patient with polycythemia vera, the estimated cost is $600 combined.
The JAK2 V617F mutation is a result of a single change in the DNA nucleotide base pair that causes a substitution of a valine amino acid for a phenylalanine amino acid at the 617 position on exon 14 within the JAK2 kinase regulatory domain.
The quantitative real-time PCR assay detects V617F mutation (c.1849 G>T) observed in approximately 95% polycythemia vera (pv), 55% essential thrombocythemia (ET), and 55% primary myelofibrosis (PMF). It is also infrequently present (3% to 5%) in myelodysplastic syndrome, chronic myelomonocytic leukemia, and other atypical chronic myeloid disorders. The results should be interpreted in the context of all clinical and laboratory findings. No therapeutic action should be taken based solely on these results.
This assay detects only the JAK2V617F point mutation. Other mutations that may occur in the JAK2 gene will not be detected. In vitro studies have indicated that this assay has an analytical sensitivity of 1%. This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
JAK2 V617F Cascading Reflex to CALR, JAK2 Exon 12, MPL, and CSF3R - This DNA-based cascading reflex identifies the disease-defining mutations in four genes used for diagnosis and follow-up of myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and chronic neutrophilic leukemia (CNL).#N#Since these mutations are essentially mutually exclusive, reporting is done in a stepwise fashion based on mutation frequencies assessing JAK2 V617F, then exon 9 of CALR (calreticulin), then exon 12 of JAK2, then codon 505 and 515 of MPL, and then two mutational hotspots in the CSF3R gene. Once a pathogenic ...
CPT Code is subject to a Medicare Limited Coverage Policy and may require a signed ABN when ordering. CPT Code is subject to a Medicare Limited Coverage Policy and may require a signed ABN when ordering. Ordering Restrictions may apply.
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
5 mL whole blood or 3 mL bone marrow aspirate collected in an EDTA (lavender-top) tube
Whole blood or bone marrow aspirate collected in: Sodium heparin (green-top) tube • Fixed cell pellet collected in: Plastic leak-proof container • Extracted DNA from CLIA-certified laboratory collected in: Sterile leak-proof container
The Janus kinase 2 gene ( JAK2) codes for a tyrosine kinase (JAK2) that is associated with the cytoplasmic portion of a variety of transmembrane cytokine and growth factor receptors important for signal transduction in hematopoietic cells . Signaling via JAK2 activation causes phosphorylation of downstream signal transducers and activators ...
Positive variant status is highly suggestive of a myeloid neoplasm, but must be correlated with clinical and other laboratory features for definitive diagnosis. Negative variant status does not exclude the presence of a myeloproliferative neoplasm or other neoplasm.